Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.

abstract：:The National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamicin (henceforth inotuzumab), to submit clinical- and cost-effectiveness evidence for inotuzumab as part of NICE's single technology appraisal process. The Centre for Reviews and Dissemination and the Cent...

journal_title：PharmacoEconomics

authors： Cox E,Wade R,Peron M,Dietz KC,Eastwood A,Palmer S,Griffin S

更新日期：2019-09-01 00:00:00

abstract：OBJECTIVE:To estimate the annual direct cost of managing erectile dysfunction (ED) to the UK National Health Service (NHS) and to examine the impact of the introduction of sildenafil in 1998 and Schedule 11 restrictions in 1999. DESIGN:A prevalence-based cost-of-illness approach was used. The period 1997 to 2000 was c...

journal_title：PharmacoEconomics

authors： Wilson EC,McKeen ES,Scuffham PA,Brown MC,Wylie K,Hackett G

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:To calculate costs for the management of deep foot infections and to identify the most important factors related to treatment costs. DESIGN:Costs for in-hospital care, surgery, investigations, antibacterials, visits to the foot-care team, orthopaedic appliances and topical treatment were calculated retrospec...

journal_title：PharmacoEconomics

authors： Tennvall GR,Apelqvist J,Eneroth M

更新日期：2000-09-01 00:00:00

abstract：INTRODUCTION:Recent clinical trial results have demonstrated that, in patients with type 2 diabetes, second-line treatment of rosiglitazone in combination with metformin can lead to significant improvements in the control of fasting plasma glucose/ glycosylated haemoglobin A1c (HbA1c) after the failure of metformin mon...

journal_title：PharmacoEconomics

authors： Beale S,Bagust A,Shearer AT,Martin A,Hulme L

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Dengue disease poses a great economic burden in Malaysia. METHODS:This study evaluated the cost effectiveness and impact of dengue vaccination in Malaysia from both provider and societal perspectives using a dynamic transmission mathematical model. The model incorporated sensitivity analyses, Malaysia-speci...

journal_title：PharmacoEconomics

authors： Shafie AA,Yeo HY,Coudeville L,Steinberg L,Gill BS,Jahis R,Amar-Singh Hss

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:The recently completed ALEX trial demonstrated that alectinib improved progression-free survival, and delayed time to central nervous system progression compared with crizotinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. However, the long-term clinical and economic impac...

journal_title：PharmacoEconomics

authors： Carlson JJ,Suh K,Orfanos P,Wong W

更新日期：2018-04-01 00:00:00

abstract：:The original article can be found online. ...

journal_title：PharmacoEconomics

authors： Paulden M

更新日期：2020-10-01 00:00:00

abstract：:Health reform is currently the predominant health policy issue in the US. It carries profound implications for the pharmaceutical field, including the possibility of price controls that could stifle pharmaceutical research. While policy makers are contemplating alternative approaches to reform, the marketplace for pha...

journal_title：PharmacoEconomics

authors： Meyer PR

更新日期：1994-01-01 00:00:00

abstract：:Drug utilisation in term and preterm neonates (i.e. less than 28 days of age) has been investigated prospectively in 4 clinical studies during the past 10 years. 3880 neonates with a mean gestational age of 34.5 weeks (corresponding birthweight 2280g) were enrolled in these studies. An overview indicates a high prev...

journal_title：PharmacoEconomics

authors： Gortner L

更新日期：1993-12-01 00:00:00

abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Sanofi Genzyme) of sarilumab (SAR; Kevzara®) to submit evidence of its clinical effectiveness and cost-effectiveness for previously treated moderate or severe rheumatoid arth...

journal_title：PharmacoEconomics

authors： Bermejo I,Ren S,Simpson E,Clowes M,Scott DL,Young A,Stevenson M

更新日期：2018-12-01 00:00:00

abstract：:A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content analysis was used to ex...

journal_title：PharmacoEconomics

authors： Oremus M,Aguilar SC

更新日期：2011-02-01 00:00:00

abstract：:Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions ...

journal_title：PharmacoEconomics

authors： Alexandrov AV,Smurawska LT,Bartle W,Oh P

更新日期：1997-05-01 00:00:00

abstract：BACKGROUND:Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. OBJECTIVE:The present review aims to systematically review published ec...

journal_title：PharmacoEconomics

authors： Plumpton CO,Roberts D,Pirmohamed M,Hughes DA

更新日期：2016-08-01 00:00:00

abstract：:There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, and methodological challenges limit its more widespread use. Common data models and federated data networks offer a potential solution to many of these ...

journal_title：PharmacoEconomics

authors： Kent S,Burn E,Dawoud D,Jonsson P,Østby JT,Hughes N,Rijnbeek P,Bouvy JC

更新日期：2020-12-18 00:00:00

abstract：OBJECTIVE:The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. DESIGN:The World Health Organization Quality of Life ...

journal_title：PharmacoEconomics

authors： Pibernik-Okanović M,Szabo S,Metelko Z

更新日期：1998-08-01 00:00:00

abstract：BACKGROUND:The symptoms of attention-deficit hyperactivity disorder (ADHD) are associated with impairment in multiple domains of health-related quality of life (HR-QOL). HR-QOL of children with ADHD has been assessed by relatively long multidimensional questionnaires. A review of the literature found no studies using t...

journal_title：PharmacoEconomics

authors： Matza LS,Secnik K,Mannix S,Sallee FR

更新日期：2005-01-01 00:00:00

abstract：:In an attempt to obtain an appropriate estimate of the excess costs of production losses arising from morbidity in patients with diabetes, we compared the number of sick days and permanently disabled individuals in a diabetic population and the corresponding general population. These comparisons show that the rate of ...

journal_title：PharmacoEconomics

authors： Persson U

更新日期：1995-01-01 00:00:00

abstract：:Open-heart surgery (OHS) is performed to bypass occluded arteries, replace malfunctioning cardiac valves or correct congenital abnormalities. The average cost of OHS varies from $US25 057-$US79 795 (1997 values). The objective of this paper was to review economic studies of pharmacological strategies in open-heart sur...

journal_title：PharmacoEconomics

authors： Reddy P,Song J

更新日期：2003-01-01 00:00:00

abstract：:Cost-effectiveness analysis (CEA) is one of the main tools of economic evaluation. Every CEA is based on a number of assumptions, some of which may not be accurate, introducing uncertainty. Sensitivity analysis (SA) formalizes ways to measure and evaluate this uncertainty. Specific sources of uncertainty in CEA have b...

journal_title：PharmacoEconomics

authors： Jain R,Grabner M,Onukwugha E

更新日期：2011-04-01 00:00:00

abstract：:In the current climate of cost containment and quality control, nosocomial infection is a worrisome adverse event in hospital care. Hospitalised patients require care for increasingly severe illnesses, and are therefore more susceptible to infection, especially by opportunistic micro-organisms. It is thus necessary to...

journal_title：PharmacoEconomics

authors： Gálvez-Vargas R,Bueno-Cavanillas A,García-Martín M

更新日期：1995-02-01 00:00:00

abstract：BACKGROUND:In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government. METHODS:We conducted a ...

journal_title：PharmacoEconomics

authors： Laba TL,Reddel HK,Zwar NJ,Marks GB,Roughead E,Flynn A,Goldman M,Heaney A,Lembke K,Jan S

更新日期：2019-02-01 00:00:00

abstract：OBJECTIVE:Pertussis is a highly contagious infection affecting mainly children. Acellular pertussis vaccines were recently introduced in Canada based on evidence of improved safety and efficacy over whole cell vaccines, the current standard of care. The following study reports the economic impact of replacing the whole...

journal_title：PharmacoEconomics

authors： Iskedjian M,Einarson TR,O'Brien BJ,De Serres JG,Gold R,Gemmill IM,Milkovich N,Rosner A

更新日期：2001-01-01 00:00:00

abstract：:This willingness-to-pay (WTP) analysis is the first study of its kind undertaken in Australia to support an application for listing of a new drug on the Australian national formulary. The technique offers the advantage of being able to summarise diverse outcomes of therapy in a single unit of measure. Willingness to p...

journal_title：PharmacoEconomics

authors： Davey P,Grainger D,MacMillan J,Rajan N,Aristides M,Dobson M

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND:Recent randomised trials have demonstrated a statistically significant effect of trastuzumab on disease-free survival when used as adjuvant therapy for human epidermal growth factor receptor 2 protein (HER2)-positive resectable early stage breast cancer, with a treatment course lasting either 9 or 52 weeks. ...

journal_title：PharmacoEconomics

authors： Millar JA,Millward MJ

更新日期：2007-01-01 00:00:00

abstract：:Scientific reviewing methods were applied to economic studies of influenza vaccination, and an economic model of influenza vaccination was developed from these primary sources. Issues arising from the secondary literature review include the quality of evidence on the effectiveness of the vaccines, the absence of a tra...

journal_title：PharmacoEconomics

authors： Jefferson T,Demicheli V

更新日期：1996-01-01 00:00:00

abstract：BACKGROUND:Simulation models utilizing real-world data have potential to optimize treatment sequencing strategies for specific patient subpopulations, including when conducting clinical trials is not feasible. We aimed to develop a simulation model to estimate progression-free survival (PFS) and overall survival for fi...

journal_title：PharmacoEconomics

authors： Degeling K,Wong HL,Koffijberg H,Jalali A,Shapiro J,Kosmider S,Wong R,Lee B,Burge M,Tie J,Yip D,Nott L,Khattak A,Lim S,Caird S,Gibbs P,IJzerman M

更新日期：2020-11-01 00:00:00

abstract：INTRODUCTION:Mixture modelling is increasingly being considered where a potential cure leads to a long life. Traditional methods use relative survival models for frail populations or cure models that have improper survival functions with theoretical infinite lifespans. Additionally, much of the work uses population dat...

journal_title：PharmacoEconomics

authors： Grant TS,Burns D,Kiff C,Lee D

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Lung cancer is among the top causes of cancer-related deaths. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free survival compared with standard chemotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). OBJECTIVE:The aim o...

journal_title：PharmacoEconomics

authors： Schremser K,Rogowski WH,Adler-Reichel S,Tufman AL,Huber RM,Stollenwerk B

更新日期：2015-11-01 00:00:00

abstract：:To review and critically evaluate published cost-utility analyses (CUAs) pertaining to pharmaceuticals for the past 3 decades. We examined data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on English-language CUAs and their ratios (in $US...

journal_title：PharmacoEconomics

authors： Neumann PJ,Fang CH,Cohen JT

更新日期：2009-01-01 00:00:00

abstract：:The objective of this study was to compare the cost effectiveness of amoxicillin/clavulanic acid with other antibacterial regimens for prophylaxis of infection after elective abdominal or gynaecological surgery. Data from 21 previously published comparative clinical trials were used to calculate statistical confidence...

journal_title：PharmacoEconomics

authors： Davey PG,Parker SE,Crombie IK,Jaderberg M

更新日期：1995-04-01 00:00:00